RAS Mutation Detection Kit Market

RAS Mutation Detection Kit Market Study by PCR-Based Kits, Sequencing-Based Kits, and Hybridization & Allele-specific PCR from 2024 to 2034

Analysis of RAS Mutation Detection Kit Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

RAS Mutation Detection Kit Market Outlook (2024 to 2034)

The global RAS mutation detection kit market size is set to be valued at US$ 118.7 million in 2024 and is projected to expand at a noteworthy CAGR of 7.6% to reach US$ 246.7 million by 2034-end.

RAS mutation detection kits are specialized laboratory instruments designed to detect changes in the RAS gene family, a set of genes commonly altered in different types of cancer like colorectal cancer or pancreatic cancer. RAS mutations affect how cells divide and proliferate, which may result in undiagnosed cell growth and the development of tumors. The RAS mutation gene can be further divided into three major types namely KRAS, NRAS, and HRAS mutation genes.

  • The KRAS type is estimated to hold a leading market share of 76.5% in 2024, and the segment is projected to expand at a CAGR of 7.2% during the forecast period (2024 to 2034).

Demand for RAS mutation screening kits is being bolstered by the goal of early cancer detection. To provide patients a chance of having a successful course of therapy, these kits help in identifying the patients who show symptoms as soon as possible. Cancer care that is postponed has shorter survival rates, more treatment-related problems, and higher healthcare costs.

Colorectal cancer is the most common type of cancer and exhibits the highest incidence of RAS mutation cells. Rising prevalence of these chronic diseases among the population is driving the need for advanced diagnostic testing kits for tumor marker detection. Furthermore, ongoing research and development activities in cancer diagnostics are projected to offer more diverse and effective options.

  • North America is projected to account for 38.6% of the global RAS mutation detection kit market share by 2034.
  • Revenue from RAS mutation analysis kit sales in Latin America is estimated to reach US$ 3.8 million in 2024.
Report Attributes Details
RAS Mutation Detection Kit Market Size (2024E) US$ 118.7 Million
Forecasted Market Value (2034F) US$ 246.7 Million
Global Market Growth Rate (2024 to 2034) 7.6% CAGR
Canada Market Growth Rate (2024 to 2034) 7.1% CAGR
Chile Market Value (2034F) US$ 1.2 Million
NRAS Mutation Segment Growth (2024 to 2034) 9.1% CAGR
Key Companies Profiled
  • EntroGen, Inc.
  • QIAGEN
  • Roche Molecular Diagnostics
  • Bio-Rad Laboratories
  • Personalis, Inc.
  • Thermo Fisher Scientific
  • MBL Life Sciences
  • Amoy Dx
  • 3B BlackBio Biotech India Limited
  • CD Genomics

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which RAS Mutation Detection Kit Market Trends are Suppliers Benefitting from?

“Increased Patient Awareness of Role of RAS Mutation in Cancer Development”

Patients proactively seek diagnostic testing to find out whether they have an RAS mutation as awareness of this mutation's role in the development of cancer is rising. Better results may come from customized therapy regimens based on the unique genetic composition of the tumor, which is made possible by this early detection. This is why genetic testing for cancer has gained traction in recent times in the oncology diagnostics spaces.

People who are aware of the risk factors and typical symptoms of cancer are more likely to seek medical assistance as soon as they notice any anomalies. This enables early diagnosis and management at the initial stages.

“Government Initiatives Promoting Early Cancer Diagnosis and Favorable Reimbursement Policies”

Governments are starting to realize how important tailored treatment and early cancer diagnosis are. This translates into practical action in the form of RAS testing-promoting public health campaigns, infrastructure improvements in the healthcare industry, and even direct support for RAS detection technology research and development. Rising awareness and accessibility of these kits foster a favorable environment for expansion of the RAS mutation detection kit market size.

More patients can now benefit from RAS testing and genetic mutation testing because reimbursement policies are lessening the financial burden. Insurance companies are beginning to see the value of early identification and treatment.

What is Hampering Global RAS Mutation Detection Kit Market Growth?

“Technical and Operational Challenges Impeding Adoption of RAS Mutation Detection Kits”

The market faces substantial obstacles due to operational and technical issues. Even while more recent methods claim to be more accurate, certain older kits still have problems with false positives or negatives, which could be confusing and detrimental to patient treatment.

Complicated data interpretation puts more pressure on the system since it calls for specialist knowledge that isn't always available. There are logistical and budgetary obstacles when integrating RAS mutation tests into current laboratory operations and making sure the equipment is compatible. Additional investments and modifications are frequently needed.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Which Key Strategies are Proving Instrumental in Propelling New Companies to Success?

“Focus on Research Collaborations to Develop Advanced RAS Mutation Detection Kits”

New companies can take advantage of complementary strengths in research & development (R&D), assay design, production, and clinical validation by combining resources and expertise. This encourages the development of increasingly sophisticated, precise, and user-friendly RAS mutation detection kits that meet a range of requirements.

  • For instance, Entrogen, Inc.'s ctDNA RAS mutation detection kit is a non-invasive, highly sensitive assay that amplifies and detects 25 clinically relevant mutations in KRAS exon 2 and NRAS exons 2 and 3 from circulating cell-free DNA obtained from human plasma.

Encouraging new businesses to actively participate in and fund clinical trials can not only aid in the creation of innovative products but also boost the company's reputation. Favorable trial results are projected to fortify the argument for regulatory endorsements and cultivate confidence among healthcare professionals.

Forming partnerships with research institutions and industry leaders facilitates the exchange of knowledge and grants access to complementary expertise. These collaborations expedite research and development activities, empowering emerging manufacturers to efficiently introduce innovative solutions to the market, thereby enhancing the availability of RAS mutation detection kits.

Country-wise Analysis

As per the analysis by Fact.MR, a market research and competitive intelligence provider, market growth in the United States, Germany, and Brazil is influenced by a combination of factors, including the presence of advanced healthcare infrastructure, next generation sequencing, research initiatives, government support, awareness campaigns, and patient access to innovative therapies.

Why are RAS Mutation Detection Kit Providers Focusing on the United States?

“Increasing Prevalence of Cancer and Enhanced Patient Access to Advanced Treatments”

Attribute United States
Market Value (2024E) US$ 40.6 Million
Growth Rate (2024 to 2034) 7.8% CAGR
Projected Value (2034F) US$ 86.9 Million

Surging cancer rates in the United States are driving a heightened need for efficient diagnostic testing targeting RAS mutations. Key contributors to the escalating cancer prevalence include the aging demographic and evolving lifestyles. Supportive reimbursement policies in the country are facilitating patient access to advanced treatment alternatives.

What is Complementing Market Growth in Germany?

“Emphasis on Research and Innovation and Collaborative Healthcare Ecosystem”

Germany's commitment to medical research and innovation is solidifying its role as a frontrunner in European healthcare. The ongoing surge in research-driven breakthroughs, particularly in cancer diagnostic testing, is playing a pivotal role in driving market expansion. The collaborative healthcare ecosystem in the country, fostering strong ties between academia, industry, and healthcare providers, is creating an ideal environment for the advancement and uptake of RAS mutation detection kits.

Why is Brazil a Lucrative Market for RAS Mutation Detection Kit Providers?

“Government Initiatives for Cancer Control Contributing to Early Detection and Treatment”

Attribute Brazil
Market Value (2024E) US$ 1.7 Million
Growth Rate (2024 E to 2034 F) 5.4% CAGR
Projected Value (2034F) US$ 2.9 Million

Increasing initiatives to enhance cancer awareness in Brazil are leading to early detection and treatment. Government programs dedicated to cancer control and treatment accessibility are pivotal in shaping efficient diagnostic solutions. Globally recognized events like World Cancer Day, observed annually, aim to intensify efforts for better access to top-notch care, screening, early detection, treatment, and palliative care.

Robust investments in healthcare infrastructure, awareness initiatives, and supportive policies collectively contribute to a holistic approach to the development and utilization of RAS mutation detection kits.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Category-wise Analysis

Increased demand for KRAS mutation detection kits is propelled by factors including improved effectiveness, varied treatment strategies, the rise of personalized medicine, and positive outcomes from successful clinical trials. As ongoing research and development persist, detection of the KRAS mutation gene plays a pivotal role in molding the contemporary landscape of cancer diagnostic kits.

Which RAS Type Occupies a Leading Market Share?

“Increased Incidence of Cancer Cases Due to Unchecked Proliferation Due to KRAS Mutations”

Attribute KRAS Type
Segment Value (2024E) US$ 90.8 Million
Growth Rate (2024 to 2034) 7.2% CAGR
Projected Value (2034F) US$ 181.5 Million

The KRAS gene, located on chromosome 12, is prone to damage from a variety of factors, such as smoking, UV radiation, and even regular biological functions. This inherent susceptibility increases the likelihood of mutations occurring in the KRAS gene. KRAS mutations frequently give cancer cells an advantage in terms of proliferation. These mutant cells outcompete their non-mutated counterparts by encouraging unchecked proliferation, which increases the number of cancer cases.

Competitive Landscape

Key players in the RAS mutation detection kit market are strategically emphasizing research excellence, forming key collaborations, expanding globally, adopting patient-centric approaches, demonstrating regulatory expertise, implementing market-specific pricing strategies, and integrating technology. These diverse strategies are designed to enable industry leaders not just to navigate the intricacies of the market but also to stimulate innovation and make substantial contributions to the progress of RAS mutation detection kits.

Key Segments of RAS Mutation Detection Kit Market Research

  • By RAS Type :

    • NRAS
    • KRAS
    • HRAS
  • By Application :

    • Disease Diagnostics
    • Prognostics
    • Personalized Medicine
    • Drug Discovery & Development
  • By Cancer Type :

    • Breast Cancer
    • Pancreatic Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Blood Cancer
    • Skin Cancer
    • Uterus Cancer
    • Bladder Cancer
    • Prostate Cancer
  • By Kit Type :

    • Tissue-based Kits
    • Liquid Biopsy Kits
  • By End User :

    • Academic & Cancer Research Institutes
    • Hospitals & Diagnostic Clinics
    • Contract Research Organizations
    • Pharma & Biotech Companies
  • By Detection Method :

    • PCR-Based Kits
    • Sequencing-Based Kits
    • Hybridization and Allele-specific PCR
  • By Region :

    • North America
    • Latin America
    • East Asia
    • South Asia & Pacific
    • Western Europe
    • Eastern Europe
    • Middle East & Africa

- FAQs -

How big is the RAS mutation detection kit market in 2024?

The global RAS mutation detection kit market is estimated at US$ 118.7 million in 2024.

What is the sales value of RAS mutation detection kit solutions in Brazil?

Sales of RAS mutation detection kits in Brazil are calculated at US$ 1.7 million for 2024.

What is the projected revenue from RAS mutation detection kit sales by 2034?

Worldwide revenue from RAS mutation detection kits sales is forecasted to reach US$ 246.7 million by 2034 end.

What is the demand growth projection for the global market?

Demand for RAS mutation detection kits solutions is forecasted to rise at a CAGR of 7.6% during the next 10 years.

Which RAS mutation detection kit type is most widely preferred?

Tissue-based kits are widely popular due to their efficiency and safe results.

Who are the key players in the RAS mutation detection kits?

Leading companies in the market are EntroGen Inc., QIAGEN, Roche Molecular Diagnostics, Bio-Rad Laboratories, Personalis, and Thermo Fisher Scientific.

- Also of Interest -

Genetic Testing Services Market

Genetic Testing Services Market Analysis by Prenatal Testing, New Born Screening, Predictive & Presymptomatic Testing, and Pharmacogenomic Testing from 2023 to 2033

Colorectal Cancer Diagnostics Market

Colorectal Cancer Diagnostics Market Report By Test Type (Colorectal Cancer FOB Tests, Colorectal Cancer CTC Tests, Colorectal Cancer CEA Tests, Colorectal Cancer BRAF V600 Mutation Tests, KRAS Mutation Tests), By End User - Forecast to 2021–2031

Breast Cancer Diagnostics Market

Breast Cancer Diagnostics Market Analysis by Test Type (CA Tests, BRCA Test, ER & PR Test, CEA Test, KRAS Mutation Test, HER 2 Test, PSA Test, EGFR Mutation Test, Immunohistochemistry for Breast Cancer), by End-User & Region - Global Forecast 2022-2032

Oncology Molecular Diagnostics Market

Oncology Molecular Diagnostics Market By Product (Oncology Molecular Diagnostic Reagents & Kits, Instruments, Services & Software), By Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH)), By End User, By Region - Global Insights to 2031

RAS Mutation Detection Kit Market

Schedule a Call